Abstract: This invention discloses “Artificially Cleaved Epitope (ACE)” methods, antibodies, reagents, immunoassays, and kits for designing and detecting mutation-specific epitopes/antigens. The ACE methods can detect epitopes that are either absent or poorly recognizable or accessible naturally to antibodies, and thus must be specifically and artificially created (free terminals) and/or exposed in samples and sample preparations for antibody detection. The ACE methods comprise ACE antigen design and ACE antigen detection. The ACE methods, antibodies, reagents, immunoassays, and kits are useful in research and discovery, diagnostic, and therapeutic applications. In another aspect, the ACE methods can artificially and specifically expose hidden antigens while reducing the antibody non-specific bindings in all antibody-based applications.

Abstract: The invention provides surfactant compounds of formulas I-IX, which can be used in methods for aiding the solubilization, digestion, preparation, analysis, and/or characterization of biological material, for example, proteins or cell membranes. The compounds can also aid in the recovery of peptides generated during protein digestion, particularly for in-gel digestion protocol. Additionally, the compounds can improve enzymatic protein deglycosylation without interfering with downstream sample preparation steps and mass spectrometric analysis. The compounds can be specifically useful as digestion aids that can be decomposed by an acid, by heat, or a combination thereof. Decomposition of the surfactants allows for facile separation from isolated samples, and/or allows for analysis of the sample without interfering with the sensitivity of various analytical techniques.

Abstract: Provided herein are cell-permeable, cell-compatible, and chemoselectively-cleavable linkers for tethering (e.g., covalently) functional elements (e.g., a cellular interaction element and a capture element), and methods of use (e.g., intracellular capture and extracellular release of cellular targets) therewith.

Abstract: Methods for in situ detecting proximity of two targets of interest featuring an antibody conjugated with a cleavable bridge component having a detectable moiety and an antibody conjugated with a non-cleavable bridge component. The bridge components each have a chemical ligation group adapted to form a covalent bond under particular conditions and when the targets are in close proximity. Following covalent bond formation, the cleavable bridge component can be cleaved from the antibody, effectively transferring the detectable moiety to the non-cleavable bridge component. Detection of the detectable moiety is indicative of the targets being in close proximity. The methods are compatible with both chromogenic and fluorogenic detection systems. The methods may be used to perform assays wherein one or more than one proximity event is detected on the same slide.

Abstract: The present application provides stable peptide-based IL-17F capture agents and methods of use as detection agents. The application further provides methods of manufacturing IL-17F capture agents.

Abstract: The present invention is intended to provide an immunoassay method that enables an immunoassay with high sensitivity at a high development rate without causing aggregation of insoluble carriers or non-specific reaction while improving test efficiency and reducing labor. The present invention relates to an immunoassay method that uses a test device, and the method includes: extracting an antigen of a detection target in an analyte with an extraction agent; and detecting the detection target with a detection reagent capable of binding the antigen. The extraction agent is a nitrous acid generated on the test device by a contact reaction between a nitrite salt and a heterocyclic compound having at least one skeleton selected from the group consisting of a cyclic ester, a cyclic amide, and a cyclic imide.

Abstract: Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.

Abstract: The present disclosure provides isolated antibodies that bind to acetaminophen-protein adducts that are useful in the detection and diagnosis of acetaminophen-induced toxicity.

Abstract: The invention includes monoclonal and polyclonal antibodies, and antigen-binding fragments thereof, having specific binding affinity for 4,6-diamino-5-(formylamino)pyrimidine (FAPY-adenine); hybridomas producing such antibodies; immunoconjugates comprising an antibody or antigen-binding fragment of the invention coupled to a moiety; and in vitro and in vivo methods for using such antibodies, antibody fragments, and conjugates based on binding to FAPY-adenine; nucleic acids encoding the heavy and/or light chains of the antibodies; vectors comprising the nucleic acid sequences encoding the heavy and/or light chains; host cells comprising and, optionally, expressing the nucleic acid sequences; and methods for the production of the aforementioned materials.

Abstract: This invention is directed to monomolecular sensors, comprising a selective binder, a non-selective binder and a fluorophore, which can track changes that occur on the surface of labeled proteins. This invention is further directed to the use of such sensors for identifying binding partners of specific proteins. This invention is further directed to His-tag binding compounds and uses thereof in the preparation of genetically targeted detectable molecules and sensors which can specifically bind tag-labeled proteins.

Abstract: Provided are artificially synthesized modified mono-methylated lysines and modified mono-methylated lysine derivatized polypeptides. Also provided is an antibody produced by using this modified mono-methylated lysine and modified monomethylated lysine derivatized polypeptide as an antigen, the antibody can be used in recognizing and enriching the modified polypeptide after the lysine mono-methylated polypeptide being derivatized in vitro. Also provided are a preparation method of said antibody, a method for identifying and quantifying the lysine mono-methylated modified substrate in cell or tissue by using proteomics approach of affinity enrichment for specific antibody and mass spectrometry.

Abstract: Processes and compositions are described for preparing new, colloidally stable, coated nanomagnetic particles useful for both in-vitro and in-vivo biomedical applications, including cell targeting and capturing cells, microorganisms, and cellular organelles or entities such as exosomes. These nanomagnetic particles can also be used as imaging contrast agents due to their small size and high magnetic moment. The nanomagnetic particles include a series of sequentially added, stabilizing surface coatings rendered onto nano-sized magnetic crystal clusters (e.g., magnetite particles) to impart colloidal stability in complex biological samples with minimal leaching of the coating materials, high binding capacity, and low non-specific binding. Another benefit of this invention is the ability to utilize both external and internal magnetic field-generating separation devices to effect separation of the magnetic nanoparticles.

Abstract: The present disclosure provides an extraction coating for an SPME sampling instrument, where the extraction coating includes a sorptive material immobilized in a fluorocarbon polymer that is compatible with thermal-assisted desorption techniques, solvent-assisted desorption techniques, or both. The disclosure also provides SPME sampling instruments, methods of making an SPME sampling instrument, and methods of extracting an analyte from a sample matrix using the SPME coating.

Abstract: NNA-derived specific adducts represent an integrated biomarker of exposure to thirdhand smoke (THS) as NNA is unique to THS. The NNA-dG covalent binding adduct could serve as such a biomarker, and play a role in identifying individuals exposed to THS, thus providing critical information for early detection and prevention.

Abstract: Disclosed are methods for detecting remnant cancer cells in a tissue sample.

Abstract: The present disclosure provides semiconductor-metal composite nanoparticles with optical properties that are superior to those of pure materials for use as contrast agents. The composites include noble metal nanoparticles having a layer of linker molecules being bound to the surface of the noble metal nanoparticle and a layer of dye molecules bound to the layer of linker molecules. The dye molecules are selected such that they form an ordered structure that exhibits a collective absorption band shift, compared to the individual dye molecule, when bound to the noble metal nanoparticle. This structure is encapsulated in a stabilizing coating layer forming a multi-shell structure with properties suitable for biosensing and other detection applications which exhibit enhanced Raman scattering compared to nanoparticles having dye molecules bound thereto not in the ordered structure.

Abstract: This invention relates to a rare earth nanomaterial labeled biomolecule, its labeling method and a dissolution-enhanced time-resolved fluoroimmunoassay based on the rare earth nanomaterial. The rare earth nanomaterial serves as a label having stable properties, large specific surface area, strong modifiability, low-cost and thousands of lanthanide ions contained in each nanocrystal, the labeling ratio of rare earth ions can be greatly improved.

Abstract: Provided are: a phosphor-integrated nanoparticle labeling agent which is capable of yielding a sufficient signal intensity even when its final concentration in an immunofluorescent staining reaction system is low (e.g., 0.02 nM) and enables to obtain an immunofluorescently stained image with reduced noise by inhibiting non-specific adsorption of a probe biological substance and a label to substances other than a detection subject; and an immunostaining method using the same. The phosphor-integrated nanoparticle labeling agent is a set which includes: a probe biological substance 3, which is linked to a first binding group substance A via a first hydrophilic polymer-derived spacer 1 having a length of 30 ? to 1,000 ? and specifically binds to a biomolecule 2; and a phosphor-integrated nanoparticle 5, which has a second binding group substance B capable of specifically binding to the first binding group substance A.

Abstract: A hydroxyl-covered silicon quantum dot nanoparticle having a silicon core, a plurality of silicon quantum dots, and a plurality of hydrocarbon chains is illustrated. A first portion of a surface associated with the silicon core is passivated by a plurality of silicon hydroxyl groups (Si—OH). The silicon quantum dots are attached to a second portion of the surface associated with the silicon core. The hydrocarbon chains are bonded to each of the silicon quantum dots through a plurality of silicon carbide bonds (Si—C), wherein each termination of the hydrocarbon chains has a carbon hydroxyl group (C—OH), such that the hydroxyl-covered silicon quantum dot nanoparticle is thoroughly covered by the carbon hydroxyl groups (C—OH) and the silicon hydroxyl groups (Si—OH).

Abstract: Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.